Geron Corporation
USUSDGeron Corporation (LSE:0IV3) — Biotechnology: Pharmaceutical Preparations. Liczba giełd, na których notowane są akcje spółki: 2. Na tej stronie — cena i wykres, dywidendy, najwięksi akcjonariusze oraz historia liczby akcji.
- Geron Co Ltd — 002722 · SHE CN Numer rejestracyjny nieznany
O Firmie
- Strona
- geron.com
- Relacje Inwestorskie
- ir.geron.com/investor-relations
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Siedziba
- Foster City, United States
- Zarząd
- Pracownicy
- 258
- Założona
- 1990
- Akcje w Obrocie
- 642.47 mln na 2026-07-31
- Free Float
- 556.32 mln
- Kapitalizacja Rynkowa
- 790.24 mln USD
- Insiderzy
- 0.08%
- Inwestorzy Instytucjonalni
- 76.63%
- Branża (SIC)
- Pharmaceutical Preparations
- Forma Prawna
- XTIQ
- ISIN
- US3741631036
- LEI
- 549300T282D7Z2YESL90
- P/E
- strata
- P/B
- 3.29
- FCF
- −115 mln USD
- Dług
- 120 mln USDujemny FCF — brak pokrycia
- Zyski i FCF — za 12 miesięcy do 30.06.2026 roku (najnowszy raport firmy).
- NAV
Opis
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Najwięksi Akcjonariusze
| Posiadacz | Udział | Akcje | Data Raportu |
|---|---|---|---|
| Blackrock Inc. | 7.64% | 49.12 mln | 2026-06-30 |
| RA Capital Management, L… | 6.66% | 42.81 mln | 2026-06-30 |
| Soleus Capital Managemen… | 6.66% | 42.81 mln | 2026-06-30 |
| State Street Corporation | 5.58% | 35.86 mln | 2026-06-30 |
| Citadel Advisors Llc | 4.52% | 29.04 mln | 2026-06-30 |
| Vanguard Capital Managem… | 4.24% | 27.25 mln | 2026-06-30 |
| SPDR SERIES TRUST-State… | 3.58% | 23.03 mln | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 3.18% | 20.45 mln | 2026-06-30 |
| ClearBridge Investments,… | 3.06% | 19.65 mln | 2026-06-30 |
| Eversept Partners, LP | 2.91% | 18.72 mln | 2026-06-30 |
| Goldman Sachs Group Inc | 2.59% | 16.63 mln | 2026-06-30 |
| Geode Capital Management… | 2.27% | 14.56 mln | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.22% | 14.26 mln | 2026-08-31 |
| Vanguard Explorer Fund | 2.02% | 12.98 mln | 2026-07-31 |
| Legg Mason Partners Inve… | 0.98% | 6.32 mln | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 6.11 mln | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.95% | 6.1 mln | 2026-07-31 |
| Fidelity Select Portfoli… | 0.85% | 5.45 mln | 2026-07-31 |
| iShares Trust-iShares Ru… | 0.81% | 5.18 mln | 2026-08-31 |
| iShares Trust-iShares Bi… | 0.73% | 4.67 mln | 2026-08-31 |
| SPIEGEL ROBERT J (Direct… | ≈0.03% | 205 810 | 2026-06-30 |
| SCARLETT JOHN A (Chief E… | ≈0.02% | 137 500 | 2025-02-27 |
| ZIEGLER JAMES (Officer) | ≈0.02% | 100 000 | 2025-02-27 |
| SAMUELS SCOTT ALAN (Offi… | ≈0% | 26 682 | 2025-02-27 |
| ROBERTSON MICHELLE (Chie… | ≈0% | 17 645 | 2026-02-18 |
| LAWLIS VIRGIL BRYAN JR.… | ≈0% | 13 300 | 2025-05-09 |
Zaloguj się przez Google